|
At last week's meeting legislative planning session, Healthcare Committee members identified and reviewed the following pieces of legislation :
o S.339 / H.R. 842 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage (MCED) Act, which would create a pathway for Medicare to cover MCED screenings once they are FDA approved.
o H.R.946 – ORPHAN Cures Act, which aims to protect and incentivize the development of treatments for rare diseases by amending the Inflation Reduction Act's orphan drug exclusion.
o H.R.1672 – Maintaining Investments in New Innovation Act (MINI) Act, which seeks to aims to ensure continued access to medical therapies developed with genetically targeted technology (GTT) by amending a provision in the Inflation Reduction Act that treated GTT differently from complex biologies
o H.R. 1691 - Ensuring Patient Access to Critical Breakthrough Products Act, which would Provide temporary Medicare coverage for medical devices and diagnostic tests approved or cleared under the FDA Breakthrough Devices Program
o H.R.1227 - The Alternatives to PAIN Act which seeks to ensure that non-opioid approaches are just as easily accessible as other medications.
o H.R.1509 - Accelerating Kids’ Access to Care Act of 2025 which aims to simplify the Medicaid provider enrollment process for pediatric care providers across state lines, ensuring children with complex medical conditions can access timely, specialized care without bureaucratic delays
o Ongoing efforts to promote and secure long term community health center funding
o Efforts to promote and preserve NIH funding
o Strategies for preserving Medicare and Medicaid funding.
The Healthcare Committee is actively seeking feedback regarding the bills and funding preservation efforts referenced above as we plan to chart a course for advocacy and programming in 2025. We welcome your organization's insight on the issues listed above, and ask that you please provide your feedback by Wednesday, April 9th, 2025.
| 
